The role: A new opportunity has arisen within the company for a permanent, experienced Head of Communications, who will be responsible for developing Synairgen’s internal and external communications strategy and managing execution in order to position SNG001 as a potential, near-term, valuable, COVID treatment, maximising its commercial success. This is a very exciting time for a fast growing company, and this role will be key role in the company.
The role holder will be responsible for positioning Synairgen as a thought leader in severe respiratory viral infection treatment. Outreach will focus on US, UK & European markets, creating and maintaining connections with PR, IR & PA companies, HCPs, Government and the Pharmaceutical Industry.
Be careful not to believe what you want to believe.
He may have meant one of two things: 1) SNG001 is definitely going to phase III OR 2) SNG001 commenced with phase III recruitment based on interim analysis while awaiting to be evaluated against the final day 28 graduation criteria before a decision is made to progress or to not progress to phase III. (As I mentioned last night this is a possibility if non-infused agents have been granted the same pathway as infused agents. We simply just don’t know.)
It could be that what he actually meant was that they have commenced with phase III recruitment even though SNG001 is still in phase II.
Here's why. Infused agents are allowed to commence with phase III recruitment prior to meeting the graduation criteria which is based on day 28 data of all 220 patients, provided the interim analysis which is based on 110 patients support such a move. SNG001 is an non-infused agent and the current published protocol does not allow for such a move. But, it is possible that an updated version of the protocol, although not yet published, does allow the same continuous recruitment for non-infused agents. Should that be the case then it is possible that they're already recruiting phase III patients for SNG001.
However, that does not necessarily mean that SNG001 will progress as it still has to pass the final graduation criteria.
RE: French Extavia trial result expected this month04 Jun 2021 22:17
Until the covid-19 patent is granted there is no real legal procedure, if any, available to Synairgen. Once granted they can under UK & US law claim retrospective damages should the patent have been infringed upon during the ‘pending’ phase. Not sure how the EU works. We can only hope that the patent is granted asap, especially in our key markets.
What we don’t know is how specific the covid-19 patent is with regards to the definition of interferon beta or under which circumstances treatment are prescribed.
Skeletor - Mexico & Germany are still to approve. I suspect Argentina has approved as I found an excel document listing covid-19 trial approvals last month, but it’s no longer available online. All sites in India have approved except for one. Hopefully that’ll come through this week and not lead to further delays.
I've sent an email to Consilium about the Primary and Study Completion Dates asking them to confirm which is correct and to have Synairgen correcting the protocol. Hopefully we'll get clarification soon.
It's either one of these two scenarios:
Scenario 1: Last Recruitment Date: 03 Jul 2021 Primary Completion Date: 31 Jul 2021 Study Completion Date: 01 Oct 2021 Top line results: Beginning Sep (assuming four weeks for analysis)
Scenario 2: Last Recruitment Date: 03 Sep 2021 Primary Completion Date: 01 Oct 2021 Study Completion Date: 02 Dec 2021 Top line results: Beginning Nov (assuming four weeks for analysis)
Funny how the government structure & its workings are not fully understood by so many which is why there are so many failings and will always be ... Whitehall is the cause of many many failings, but blame is always directed at ministers. How wrong.
The whole argument is based on a false narrative. The global pharma industry, irrespective of whether individual companies are competitors, are cooperating & assisting each other. The EU for example is backing investment in production facilities in Africa which they say is better than waiving patents.
Of course China & Russia would agree. Perfect opportunity to legally get their hands on Western technology.
I do find it ironic that both India & SA have significant production capacity and will be producing, yet they came up with this idea. SA will have capacity to produce 200m J&J annually.
This does pose a potential risk to us of which the extend will only be known in the future, even though the focus is on vaccine patents. It would be wrong to just simply ignore it, although I think it's a small risk. You can only hope that common sense and informed reason will be upheld by those countries opposing waiving patents. It is not the right or best solution to a perceived problem which may not even exist. According to an article published in Nature it can be deduced that sufficient annual production capacity would exist to manufacture enough vaccines for 70% of the world's population, based on two shots each. 70% require 11bn shots. It could even be achieved this year based on some predictions, provided no major hiccups although I'd say it's unlikely.
What has NOT been factored in, in this argument is that annual booster shots will only comprise of one shot and not two. So that brings annual demand down by 50%. Therefore it's plausible to predict that by 2022 annual supply would outstrip demand provided that the science on booster shots remains unchanged with regards to receiving only one shot.
According to Simply Wall Street the three biggest shareholders hold 8.9%, 5.6% and 5%. We know Polar has 8.9% and Polygon has 5%. Who could be the 5.6% unless it’s an incorrect statistic. Anyone has access to Morning Star’s latest holdings stats? It further states that the biggest 16 shareholders (Institutional Investors) hold 51% of shares.